IASLC 2020 World Conference on Lung Cancer Postponed

March 30, 2020

|

Estimated Read Time:

1–2 minutes

After careful consideration of the current situation, the IASLC Board of Directors and leadership have made the decision to postpone the IASLC 2020 World Conference on Lung Cancer (WCLC 2020), which was scheduled to take place August 9 – 12, 2020, in Singapore. At this time, the World Conference on Lung Cancer has been rescheduled to January 26 – 29, 2021 in Singapore (WCLC 2020 Singapore). Read the full statement.

About the Authors

Share this Article:

IASLC 2020 World Conference on Lung Cancer Postponed

Recent Posts

Zidesamtinib Demonstrates a High Objective Response Rate in TKI-Naïve Patients with Advanced ROS1-Positive NSCLC

T-DXd Poised for Shift to Frontline in HER2-Mutated Metastatic NSCLC

First-line Zipalertinib Plus Chemotherapy Improves PFS in NSCLC with EGFR Exon 20 Insertions

Sacituzumab Govitecan-Pembrolizumab Combination Will Not Supplant Pembrolizumab Monotherapy in PD-L1-High NSCLC

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care